Floatz logo

47 assets in Uterine Cancer

Therapeutic assets addressing Uterine Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Nivolumab
Uterine Cancer
National Cancer Institute (NCI)P2B (60)
Pembrolizumab
Uterine Cancer
Kineta Inc.P1/2CCC (55)
Cis-Diamminedichloroplatinum Ii
Uterine Cancer
Icahn School of Medicine at Mount SinaiP1/2CCC (54)
Irinotecan
Uterine Cancer
City of Hope Medical CenterP1/2CCC (54)
Belzutifan
Uterine Cancer
Dana-Farber Cancer InstituteP2CCC (53)
Binimetinib
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Capivasertib
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Cilostazol
Uterine Cancer
Emory UniversityP2CCC (53)
Crizotinib
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Dabrafenib
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Dasatinib
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Defactinib
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Fexagratinib
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Gsk-2636771
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Ipatasertib
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Larotrectinib
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Osimertinib
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Palbociclib
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Pertuzumab
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Relatlimab
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Sapanisertib
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Trametinib
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Trastuzumab
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Trastuzumab Emtansine
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Ulixertinib
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Vismodegib
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Adavosertib
Uterine Cancer
National Cancer Institute (NCI)P2CCC (52)
Carboplatin
Uterine Cancer
University Health Network, TorontoP1/2CCC (52)
Taselisib
Uterine Cancer
National Cancer Institute (NCI)P2CCC (51)
H-Gamma1 Heavy Chain Homo Sapiens (1-447) [Vh (Homo Sapiens Ighv4-59*01 (99.0%) -(Ighd) -Ighj3*02 (93.3%) T125>I (114), Cdr-Imgt [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, 9-G1V21 Ch2 Y15.1, T16, E18 (Ch1 K120 (214) (118-215), Hinge 1-15 (216-230), Ch2 M15.1>Y (252), S16>T (254), T18>E (256) (231-340), Ch3 D12 (356), L14 (358) (341-445), Chs (446-447)) (118-447)], (220-214')-Disulfide With L-Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv3-11*01 (96.8%) -Igkj4*01 (100%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (100%) Km3 A45.1, V101 (Ckappa A45.1 (153'), V101 (191')) (108'-214')]; Dimer (226-226'':229-229'')-Bisdisulfide, Produced In A Cell Line Derived From Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa
Uterine Cancer
Kineta Inc.P1/2CCC (50)
Copanlisib
Uterine Cancer
National Cancer Institute (NCI)P2CCC (49)
Sacituzumab
Uterine Cancer
Icahn School of Medicine at Mount SinaiP1/2CCC (48)
Alpha Tocopherol
Uterine Cancer
University of NebraskaP1/2CC (47)
coq10
Uterine Cancer
University of NebraskaP1/2CC (47)
Immunoglobulin G1 [240-Alanine,241-Alanine], Anti-(Human Folate Receptor ?) (Human Monoclonal Pro1184 ?1-Chain, Complex With Human Monoclonal Pro1184 ?-Chain, Dimer, 214??,214???,226,226?,232,232?,235,235?-Octakis(Thioether) With N6-[39-[Bis(1-Deoxy-D-Glucitol-1-Yl)Amino]-1-Oxo-4,7,10,13,16,19,22,25,28,31,34,37-Dodecaoxanonatriacont-1-Yl]-N2-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]-L-Lysyl-L-Valyl-N5-(Aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]Carbonyl]Oxy]Methyl]Phenyl]-L-Ornithinamide
Uterine Cancer
GenmabP1/2CC (47)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Uterine Cancer
Sensei Biotherapeutics, Inc.P1/2CC (47)
Monoclonal Antibody Neo-201
Uterine Cancer
Precision Biologics, IncP1/2CC (47)
Solnerstotug
Uterine Cancer
Sensei Biotherapeutics, Inc.P1/2CC (47)
Adriamycin
Uterine Cancer
City of Hope Medical CenterP1CC (43)
Fludeoxyglucose
Uterine Cancer
Jonsson Comprehensive Cancer CenterP1CC (43)
Fluorouracilum
Uterine Cancer
City of Hope Medical CenterP1CC (43)
kqb368
Uterine Cancer
Kumquat Biosciences Inc.P1CC (43)
Loperamide
Uterine Cancer
M.D. Anderson Cancer CenterP1CC (43)
Lunresertib
Uterine Cancer
University Health Network, TorontoP1CC (43)
Muamycin
Uterine Cancer
City of Hope Medical CenterP1CC (43)
Oxaliplatin
Uterine Cancer
City of Hope Medical CenterP1CC (43)